Management of Large B-Cell Lymphomas: A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy

TARGET AUDIENCE:
Hematologist-oncologists, pathologists, histologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with LBCL.
PROGRAM OVERVIEW:
In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:
• Review the disease state, clinical and molecular heterogeneity, and unmet needs, including the clinical and healthcare resource burden of LBCL
• Describe the mechanism of action and appraise available clinical safety and efficacy data and indications for new agents for the treatment of LBCL, especially R/R LBCL, to select optimal treatments
• Integrate approaches for identifying patients eligible for chimeric antigen receptor T-cell (CAR T-cell) therapy and applying suitable bridging therapies
• Incorporate approaches for identifying, monitoring, and managing therapy-associated toxicities and AEs, including CAR T-cell–associated toxicities, for patients with LBCL